Italy Diabetes Care Devices Market Size
|Study Period:||2017- 2028|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and it's growth?
Italy Diabetes Care Devices Market Analysis
The Italy diabetes care devices market is expected to reach about USD 1.2 billion registering a CAGR of 6.7% over the forecast period.
Within the first year since its inception, the COVID-19 pandemic was responsible for premature deaths, particularly among older individuals. Italy was the first country in Europe affected by COVID-19 and was among the countries with the highest mortality. Most people who died of COVID-19 were affected by the co-occurrence of two or more chronic conditions in the same individual. Several studies confirmed that chronic diseases like diabetes were associated with adverse outcomes in COVID-19 patients. The pandemic highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care through virtual consultations between healthcare providers and people with diabetes and the use of diabetes technology.
According to the International Diabetes Federation 2021 reports, the prevalence of diabetes in adults in Italy was approximately 9.9%. The growing diabetic population acts as a driver for diabetes care devices. In obese individuals, the fat cells in the body release pro-inflammatory chemicals, which may make the body less sensitive to the insulin it produces by disrupting the function of insulin-responsive cells. Thus, these individuals need external insulin shots and must use a monitoring device, such as a glucometer. Many complications develop due to diabetes, including stroke, kidney disease, nerve damage, hearing loss, hypertension, eye complication, foot complication, skin complication, etc.
The Italian health system is highly decentralized, with most administrative and organizational powers held by the regions. The National Diabetes Plan defines priorities and provides guidelines to improve the quality of diabetes care with a patient-centered focus. Regional and local authorities are responsible for its implementation, which varies among the 20 regions. Government policies play a critical role in improving the quality and safety of healthcare in a country at almost all levels of authority - state and local. Policy, systems, and environmental changes are essential to a long-term plan to prevent chronic diseases like diabetes.
Therefore, owing to the above factors, the studied market is anticipated to grow over the analysis period.
Italy Diabetes Care Devices Industry Segmentation
Diabetes care devices are the hardware, equipment, and software used by diabetes patients to regulate blood glucose levels, prevent diabetes complications, lessen the burden of diabetes, and enhance the quality of life. The Italy diabetes care devices market is segmented into management devices (insulin pumps (insulin pump device, insulin pump reservoir, and infusion set), insulin syringes, insulin cartridges in reusable pens, disposable insulin pens, and jet injectors) and monitoring devices (self-monitoring blood glucose (glucometer devices, blood glucose test strips, and lancets) and continuous glucose monitoring (sensors and durables)). The report offers the value (in USD million) and volume (in units million) for the above segments.
|Cartridges in Reusable Pens|
|Insulin Disposable Pens|
Italy Diabetes Care Devices Market Trends
The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period
The continuous glucose monitoring segment is expected to record a CAGR of more than 10.8% over the forecast period.
Continuous Glucose Monitoring Devices are automated glucose monitoring systems that consist of a small device that can be worn on the body and held on by an adhesive patch. The sensor part of the device includes a cannula inserted into the top layer of skin and uses interstitial fluid samples to check glucose levels. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. CGM makes it significantly easier to manage blood glucose levels by decreasing interruptions and allowing for better sleep. It also improves the mental health of patients or caregivers by reducing the overall mental load of managing diabetes, thereby enhancing the market prospects in the coming years.
The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals. These technologies overcome many limitations of self-monitoring blood glucose by fingerprick and allow one to go beyond HbA1c to check glucose control in diabetes. Furthermore, the technological advancements in continuous glucose monitoring sensors opened new scenarios to assess, off-line, the effectiveness of individual patient therapeutic plans and stimulated the development of innovative online applications. It includes hypoglycemia or hyperglycemia alert systems and artificial pancreas closed-loop control algorithms.
The Italian National Healthcare Service (NHS) is ensuring universal coverage for all citizens. People living with diabetes can access all the medicines, devices, and medical services they need with no out-of-pocket expenditure. Overall, Italy includes a well-developed system of diabetes care, with numerous diabetes centers throughout the country and treatment free at the point of delivery.
The factors above are likely to drive segment growth during the forecast period.
To understand key trends, Download Sample Report
Insulin disposable pens occupied the highest share in the management devices segment in the current year
Insulin Disposable pens occupied the highest market share of more than 43% in the management devices segment in the current year.
A disposable insulin pen contains a prefilled amount of insulin. When the pen is empty, it is thrown away. Insulin pens are much smaller, more portable than syringes, and contain the medicine preloaded into the delivery mechanism. The needles are easy to use and can be disposed of by twisting or snapping. The pens are usually color-coded, making it easier to know which type and how much insulin will be received from them. The disposable insulin pens are considered more consumer-friendly, as they are smaller and less noticeable than the classic vial-and-syringe. These devices are also more portable for consumers. Some pens are smart insulin pens that easily connect to an app on the phone to monitor blood sugar levels and remind when to take the next insulin dose.
Italian law regulates the clinical care of people with diabetes and creates a framework involving medical organizations, prevention programs, personnel training, and legal protection. The National Health Program is structured in essential levels of assistance that can be defined differently in the various regions. The National Health Program is structured in LEAs (essential levels of assistance). LEAs define all the medical assistance modalities offered by the INHS to citizens, with or without partial contributions, based on a patient's income. The Insulin pens are free for all diabetic patients in Italy, but they must still adhere to a nominal set of medical assistance guidelines that remain free of charge.
Technological development is gaining momentum in the insulin devices market. Several technological innovations were developed over many years, creating new types of devices that are much less cumbersome and more comfortable for patients than traditional ones. Such advantages helped increase these products' adoption in the Italian market.
Italy Diabetes Care Devices Industry Overview
The Italian diabetes care devices market is moderately fragmented, driven by manufacturers like Roche, Abbott, Novo Nordisk, Dexcom, Medtronic, etc., and other generic players.
Italy Diabetes Care Devices Market Leaders
Abbott Diabetes Care
Roche Diabetes Care
*Disclaimer: Major Players sorted in no particular order
Italy Diabetes Care Devices Market News
- June 2022: Cequr, the leader in wearable diabetes technology, released their newest and most innovative insulin delivery device yet, the Insulin Pen 2.0TM. The pen is small enough to be always worn on the user’s body. It also features a built-in blood glucose meter so users can track their blood sugar throughout the day.
- January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its apps. The hand-held Cobas pulse includes an automated glucose test strip reader, a camera, and a touchscreen for logging other diagnostic results. It’s designed for patients of all ages, including neonates and people in intensive care.
Italy Diabetes Care Devices Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Management Devices
5.1.1 Insulin Pump
220.127.116.11 Insulin Pump Device
18.104.22.168 Insulin Pump Reservoir
22.214.171.124 Infusion Set
5.1.2 Insulin Syringes
5.1.3 Cartridges in Reusable Pens
5.1.4 Insulin Disposable Pens
5.1.5 Jet Injectors
5.2 Monitoring Devices
5.2.1 Self-monitoring Blood Glucose
126.96.36.199 Glucometer Devices
188.8.131.52 Blood Glucose Test Strips
5.2.2 Continuous Glucose Monitoring
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Abbott Diabetes Care
7.1.2 Roche Diabetes Care
7.1.3 LifeScan Inc.
7.1.6 Arkray Inc.
7.1.7 Ascensia Diabetes Care
7.1.8 Novo Nordisk A/S
7.1.9 Eli Lilly
7.1.11 Insulet Corporation
7.1.12 Rossmax International Ltd.
- *List Not Exhaustive
7.2 Company Share Analysis
7.2.1 Self-monitoring Blood Glucose Devices
184.108.40.206 Abbott Diabetes Care
7.2.2 Continuous Glucose Monitoring Devices
220.127.116.11 Dexcom Inc.
18.104.22.168 Medtronic PLC
7.2.3 Insulin Devices
22.214.171.124 Insulet Corporation
126.96.36.199 Novo Nordisk A/S
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Italy Diabetes Care Devices Market Research FAQs
What is the study period of this market?
The Italy Diabetes Care Devices Market is studied from 2017 - 2028.
What is the growth rate of Italy Diabetes Care Devices Market?
The Italy Diabetes Care Devices Market is growing at a CAGR of 6.7% over the next 5 years.
What is Italy Diabetes Care Devices Market size in 2017?
The Italy Diabetes Care Devices Market is valued at 916 Million USD in 2017.
What is Italy Diabetes Care Devices Market size in 2028?
The Italy Diabetes Care Devices Market is valued at 1269 Million USD in 2028.
Who are the key players in Italy Diabetes Care Devices Market?
Abbott Diabetes Care, Roche Diabetes Care, LifeScan Inc., Medtronic PLC, Dexcom Inc. are the major companies operating in Italy Diabetes Care Devices Market.
Italy Diabetes Care Devices Industry Report
Statistics for the 2023 Italy Diabetes Care Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Italy Diabetes Care Devices analysis includes a market forecast outlook to for 2023 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.